The condition is characterized by an acute, subacute, or chronic eruption of sterile pustules associated with erythema and inflammation. This patient’s case represents the annular variant characterized by pustules on the periphery of expanding erythematous plaques with central healing, most often localized to the trunk.

FDA Alerts

FDA Alerts
Monday, October 23, 2017
The FDA has approved extended use of a rheumatoid arthritis drug for the treatment of adult patients with active psoriatic arthritis or active ankylosing spondylitis.
FDA Alerts
Monday, October 16, 2017
The FDA has approved an expanded indication for ustekinumab (Stelara; Janssen) for the treatment of adolescent patients 12 years or older with moderate to severe plaque psoriasis.
FDA Alerts
Tuesday, August 29, 2017
The FDA has approved adalimumab-adbm (Cyltezo), a biosimilar of Humira (adalimumab), for the treatment of multiple inflammatory diseases.
FDA Alerts
Friday, July 14, 2017
The FDA has approved an injectable treatment for moderate to severe plaque psoriasis in adult patients.

News

News
Friday, November 10, 2017
People with chronic inflammatory disorders like psoriasis and rheumatoid arthritis may have an increased risk of developing serious liver damage, a recent study suggests.
News
Wednesday, November 1, 2017
A recent study examined the impact of visceral fat on vascular inflammation in patients with psoriasis.
News
Monday, October 30, 2017
Members of the National Psoriasis Foundation’s medical board recently spoke with The Dermatologist to discuss the importance of the awareness day and its impact, as well as what patients and dermatologists can take away from the event. 
News
Friday, October 27, 2017
In an effort to increase awareness of psoriasis, The International Federation of Psoriasis Association has deemed October 29, 2017 to be World Psoriasis Day.

NPF Endorsed Articles

NPF Endorsed Articles
Tuesday, December 22, 2015
Researchers conducted a systematic literature review of 73 published studies to identify factors associated with treatment non-adherence across diseases in rheumatology, gastroenterology and dermatology.   
NPF Endorsed Articles
Monday, December 21, 2015
In a study published in American Journal of Clinical Dermatology, researchers analyzed the efficacy of adalimumab (Humira, AbbVie Inc.) in patients with psoriasis who previously received systematic therapy. 
NPF Endorsed Articles
Monday, December 21, 2015
​The prevalence of non-alcoholic fatty liver disease (NAFLD) in psoriasis patients was evaluated in a cross-sectional study, recently published in Journal of the European Academy of Dermatology and Venereology. 
NPF Endorsed Articles
Friday, December 18, 2015
Dermira, Inc., a specialty biopharmaceutical company, announced the completion of patient enrollment for the global CIMPASI-1 clinical trial of certolizumab pegol (Cimzia, UCB Inc.) in adult patients with moderate-to-severe chronic plaque psoriasis.

Research in Review

Research in Review
Thursday, November 16, 2017
The condition is characterized by an acute, subacute, or chronic eruption of sterile pustules associated with erythema and inflammation. This patient’s case represents the annular variant characterized by pustules on the periphery of expanding erythematous plaques with central healing, most often localized to the trunk.
Research in Review
Friday, September 8, 2017
Starting a support group for patients with psoriasis has many benefits and some challenges, too.
Research in Review
Wednesday, August 9, 2017
Kaiser Permanente researcher and clinician has studied how inflammatory effects of psoriasis can impact the entire body.
Research in Review
Monday, July 3, 2017
In this case, a 37-year-old man presented to the clinic seeking continuing care for a chronic, pruritic, bilateral rash. On physical examination, well-defined erythematous patches and papules with overlying scale were present on the anterior and posterior portion of the lower extremities.